Cerus Co. (NASDAQ:CERS – Get Free Report) CEO William Mariner Greenman sold 71,086 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total value of $103,074.70. Following the transaction, the chief executive officer now directly owns 4,238,672 shares in the company, valued at $6,146,074.40. This trade represents a 1.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
William Mariner Greenman also recently made the following trade(s):
- On Friday, March 7th, William Mariner Greenman sold 60,984 shares of Cerus stock. The shares were sold at an average price of $1.50, for a total transaction of $91,476.00.
- On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The stock was sold at an average price of $1.55, for a total transaction of $35,685.65.
Cerus Stock Performance
Shares of Cerus stock remained flat at $1.45 during trading hours on Monday. The stock had a trading volume of 1,979,196 shares, compared to its average volume of 1,302,541. The company’s fifty day simple moving average is $1.72 and its two-hundred day simple moving average is $1.76. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The company has a market cap of $269.40 million, a PE ratio of -13.18 and a beta of 1.56. Cerus Co. has a twelve month low of $1.38 and a twelve month high of $2.54.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price target on shares of Cerus in a research note on Friday, February 21st.
Check Out Our Latest Analysis on CERS
Institutional Trading of Cerus
Several institutional investors have recently added to or reduced their stakes in CERS. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Cerus in the fourth quarter valued at approximately $25,000. Squarepoint Ops LLC lifted its holdings in Cerus by 2,084.7% during the 4th quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company’s stock worth $759,000 after buying an additional 470,178 shares in the last quarter. Two Sigma Advisers LP boosted its position in Cerus by 249.5% in the 4th quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 181,400 shares during the period. Two Sigma Investments LP grew its stake in shares of Cerus by 121.6% in the fourth quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company’s stock worth $917,000 after acquiring an additional 326,605 shares in the last quarter. Finally, State of Wyoming increased its position in shares of Cerus by 39.1% during the fourth quarter. State of Wyoming now owns 129,840 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 36,488 shares during the period. Institutional investors and hedge funds own 78.37% of the company’s stock.
Cerus Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Read More
- Five stocks we like better than Cerus
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can TikTok Stock Picks Really Make You Rich?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- The “Quality” Rotation: Back to Basics Investing
- How to Calculate Options Profits
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.